We wish to comment on the gangliocytic paraganglioma research. Since hypoxia-inducible factor 2α gain-of-function mutations were detected in gangliocytic paraganglioma (GP) [1], as well as paraganglioma and somatostatinoma [2] , this neuroendocrine tumor may be relative tumors of paraganglioma and/or somatostatinoma. In fact, there are similar morphological and immunohistochemical features between paraganglioma and GP, except for the existence of ganglion-like cell in GP [3] . In addition, GP often shows positive immunoreactivity for somatostatin [3, 4] . To differentiate GP from paraganglioma, pathologists should consider the primary tumor site and the existence of ganglion-like cell (paraganglioma lacks ganglion-like cells, and it is very rare in the duodenum) [4] . On the other hand, morphological differences between GP and somatostatinoma make differentiation easy, and immunoreactivity for progesterone receptor and pancreatic polypeptide which is discussed below may be useful to differentiate them [5] .
